By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Meridian Bioscience, Inc. 

3471 River Hills Drive

Cincinnati  Ohio  45244  U.S.A.
Phone: 513-271-3700 Fax: 513-271-3762

Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Our products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori., foodborne diseases. and respiratory infections.

For more than 30 years, Meridian Bioscience, Inc., has established a proven track record of profitable growth and product launches designed to enhance patient well being while reducing the total outcome costs of healthcare. Meridian diagnostic products are used outside of the human body and require little or no special equipment.

We maintain market leadership by responding to emerging diseases and changing medical needs. Since 1991, Meridian has developed and introduced more than 56 innovative products. Meridian also grows through acquisition, licensing, or supply agreements that have added almost 100 new products to our catalog.

Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. We actively market our products to hospitals, reference laboratories, research centers, physician offices and diagnostics manufacturers in more than 60 countries around the world.

Our shares are traded on the NASDAQ National Market, symbol VIVO.

Key Statistics

Ownership: Public

Web Site: Meridian Bioscience
Symbol: VIVO

Company News
Meridian Bioscience (VIVO) Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China 7/20/2017 11:26:58 AM
FDA Raises Concerns About Meridian Bioscience (VIVO)'s Massachusetts Plant 7/14/2017 6:03:18 AM
Meridian Bioscience (VIVO) Expects To Report Third Quarter Fiscal 2017 Operating Results On Thursday, July 27, 2017 6/28/2017 8:33:50 AM
Meridian Bioscience (VIVO) Pays $66 Million for Magellan Diagnostics 3/25/2016 6:43:46 AM
Meridian Bioscience (VIVO) Receives FDA Clearance For New Molecular Whooping Cough Test Claims 11/19/2015 12:18:08 PM
Meridian Bioscience (VIVO) Announces Investment In Oasis Diagnostics 11/13/2015 10:42:22 AM
Meridian Bioscience (VIVO) Reports Fourth Quarter And Full-Year Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2016 Guidance 11/5/2015 12:01:35 PM
Meridian Bioscience (VIVO) Provides Net Revenues And Earnings Guidance For Fiscal 2016 9/9/2015 11:31:53 AM
Meridian Bioscience (VIVO) Elects Catherine Sazdanoff And John Mcilwraith To The Board Of Directors 8/17/2015 9:37:39 AM
Meridian Bioscience (VIVO) Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2015 Guidance 7/23/2015 10:48:17 AM